

All Country International Strategy Update

Fourth Quarter, 2022



Portfolio Activity

Among our transactions this quarter we purchased AstraZeneca, an established pharmaceutical company that has seen impressive transformation into an R&D leader, most notably within oncology. Management's willingness to develop Oxford's vaccine on a non-profit basis exemplifies a strong access to medicine mindset. We also acquired BDO Unibank in the Philippines. BDO looks well placed to benefit from strong economic growth prospects, relatively low credit penetration, and a young population. It has the country's largest business banking franchise, robust deposit funding, and opportunities for growth in consumer lending and fee income. Valuation is attractive at 1.3x book with ROE expanding towards 15%.


During the quarter, we sold Xinyi Solar on concerns related to the Chinese company's entry into the polysilicon business and the potential for excess supply of solar glass. In Europe, we sold Adidas due to structural challenges in the Chinese sports-goods market.

Portfolio Review

A composite of Boston Common's All Country International portfolios returned +13.9% before fees, modestly lagging the MSCI ACWIxUS Index ("the Index"). Stock selection in Communications Services was the largest detractor from performance. Telekom Indonesia's broadband customer growth & wireless revenues were slightly weaker than estimates. Negative sentiment was exacerbated by the Indonesian government's questioning of the company's failed but immaterial investment in GoTo. Korean SK Telecom was also a modest laggard. Stock selection in Materials was a drag on performance. Chilean lithium producer SQM weighed on performance, as lithium prices cooled, while other cyclical metals and mining rose strongly. Healthcare was another detractor from performance. Swiss pharmaceutical company Roche declined with disappointing clinical trial results for its experimental Alzheimer's drug. Stock selection in Europe ex-UK and Japan were regional negatives. French payments company Worldline and Irish food ingredient supplier Kerry were among the key detractors, along with Japanese holdings Daikin, an air conditioning manufacturer, and Hoya, a lens maker for eyeglasses and technology equipment.

Stock selection in Consumer Staples was the leading contributor to relative performance. Japanese and Swedish personal care companies Shiseido and Essity benefited from China's reopening. Stock selection in Financials also helped. Dutch bank ING was our best performer, as net interest margin and earnings forecasts increased. Insurance holdings,

Performance



	QTD	YTD	1Yr	3Yr	5Yr	7Yr	10Yr	Since Inception*
Gross	13.9%	-20.1%	-20.1%	0.4%	2.2%	5.7%	5.0%	4.3%
Net	13.8%	-20.5%	-20.5%	-0.2%	1.5%	5.0%	4.2%	3.6%
MSCI ACWIxUS	14.3%	-16.0%	-16.0%	0.1%	0.9%	4.8%	3.8%	3.2%

Annual Returns

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Gross	-20.1%	0.3%	26.3%	25.4%	-12.3%	31.5%	1.0%	-4.7%	-1.8%	17.5%
Net	-20.5%	-0.4%	25.4%	24.5%	-13.0%	30.5%	0.1%	-5.4%	-2.5%	16.7%
MSCI ACWIxUS	-16.0%	7.8%	10.7%	21.5%	-14.2%	27.2%	4.5%	-5.7%	-3.9%	15.3%

Portfolio Characteristics

	Boston Common	MSCI ACWIxUS
# Holdings	61	2,256
Valuation		
Price/EPS (NTM)	13.3	12.5
Enterprise Value/EBITDA (NTM)	8.3	7.6
Price/Book	1.9	1.8
Price/Sales	1.7	1.4
Dividend Yield	2.6%	3.0%
Growth		
3yr EPS Consensus Growth	6.1%	3.4%
3yr Sales consensus Growth	6.6%	5.8%
Quality		
Beta**	1.05	1.00
LT Debt to Cap.	29.8%	29.0%
Net Debt to EBITDA	1.3	1.3
Return on Equity	12.2%	14.1%
Earnings Variability***	23.6%	27.1%
Free Cash Flow Yield	7.3%	5.3%

Strategy Vehicle Options

Separate Account, Commingled Fund, Model/ADR, Mutual Fund¹

¹Subadvised by Boston Common

Source: APX Advent Portfolio Exchange. Past performance does not guarantee future results. All investments involve risk, including the risk of losing principal. *Since Inception: December 31, 2010, **The Beta calculation is based on the trailing five-year performance of a representative account within a portfolio's strategy, ***Variability is calculated as the mean absolute difference between actual earnings per share and a five-year historical growth trendline, expressed as a percentage of trendline

Portfolio Review (continued)

AXA in France and Ping An in China, also outperformed. Novo-Nordisk was a key contributor, as its Insulin medicine can be adapted for obesity therapy. Other strong performers included Danish wind turbine manufacturer Vestas, German semiconductor company Infineon, and Korean EV battery maker LG Chem, all suppliers to renewable energy and electrification projects. Regionally, Emerging Markets helped performance modestly, which included HDFC Bank in India in addition to names noted above.

Outlook and Positioning


Investment conditions may improve next year with lower inflation and peaking monetary policy pressure. China's recovery from Covid lockdown should help offset domestic weakness for key trading partners in Europe and Asia. Nevertheless, Europe still likely faces a recession, as higher costs squeeze consumers and businesses. Geopolitical risks remain elevated, exemplified by Ukraine's ongoing struggles. Encouragingly, Russia's weaponization of fossil fuel supplies has enhanced the urgency of climate change actions and upgraded prospects for key net-zero initiatives. Our portfolios have broad exposure to enablers and developers of renewable power, electrification, and energy efficiency.

Our approach balances long-term opportunities and risks with cyclical considerations. We are overweight the Healthcare and Technology sectors, which benefit from demographic trends and secular growth prospects. We continue to favor Financials, given the sector's positive leverage to rising rates, while our sizable allocation to Industrials focuses on environmental solutions providers. In all sectors, our research emphasizes companies with leading ESG practices, healthy end-market demand, and strong franchises.


Contributors & Detractors

Top 10	% of Capital	Return	Relative Contrib.	Sector
ING GROEP N.V.	1.9%	40.1%	0.41%	Financials
NOVO NORDISK A/S	2.0%	34.2%	0.34%	Healthcare
VESTAS WIND SYSTEM	1.0%	55.4%	0.33%	Industrials
AXA	2.8%	26.3%	0.30%	Financials
LG CHEMICAL	2.4%	26.8%	0.26%	Materials
SHISEIDO CO LTD	1.2%	40.4%	0.26%	Consumer Staples
INFINEON TECHNOLOG	1.5%	36.4%	0.25%	Technology
NASPERS	1.6%	32.4%	0.24%	Consumer Discretionary
PING AN INSURANCE	1.5%	32.5%	0.22%	Financials
SAP SE	2.4%	24.8%	0.22%	Technology
			2.82%	

Sector Allocation



Regional Allocation



Bottom 10	% of Capital	Return	Relative Contrib.	Sector
TELKOM INDONESIA	1.9%	-17.9%	-0.64%	Communication Services
PERSERO TBK				
ROCHE HLDGS	3.4%	-4.4%	-0.62%	Healthcare
SOCIEDAD QUIMICA MINERA DE CHILE	2.0%	-12.0%	-0.49%	Materials
ITAU UNIBANCO HLDG SA	1.5%	-8.9%	-0.32%	Financials
DAIKIN INDUSTRIES	1.9%	-0.5%	-0.28%	Industrials
BYD COMPANY LTD	1.6%	-0.3%	-0.24%	Consumer Discretionary
HOYA CORP	1.6%	0.5%	-0.22%	Healthcare
WORLDLINE	1.1%	-2.2%	-0.19%	Technology
KERRY GROUP	1.4%	0.6%	-0.18%	Consumer Staples
TAIWAN SEMICONDUCTOR	2.7%	8.7%	-0.17%	Technology
			-3.36%	

Source: APX Advent Portfolio Exchange. Past performance does not guarantee future results. All investments involve risk, including the risk of losing principal.

The information in this document is not a recommendation to buy or sell any security. There is no assurance that securities discussed will remain in a strategy upon receiving this document. Securities discussed represent only a portion of a strategy's holdings. It should not be assumed that securities transactions discussed were or will be profitable. Composite returns are presented in U.S. dollars, net of transaction costs, management fees and withholding taxes, with interest and dividends accrued. Returns for periods greater than one year are annualized. This product invests in foreign securities, which are subject to special currency, political and economic risks. The MSCI ACWI ex. U.S. Index is a free-float adjusted, market capitalization weighted index of the largest publicly traded companies listed on the exchanges of developed and emerging market countries around the world, excluding U.S.-based companies. The index is unmanaged and does not incur management fees, transaction costs, or other expenses associated with separately managed accounts. The composition of our composite varies from the composition of the Index because of differences in sector and industry exposure, risk, volatility and holdings. Boston Common claims compliance with Global Investment Performance Standards (GIPS®). For a full listing of Boston Common's composites and to request a GIPS® Compliant presentation, please call 617-720-5557.

